SGLT2 inhibition was associated with reduced 5-year risk for stroke among patients with concomitant atrial fibrillation and diabetes, according to a study in the Journal of the American Heart Association. “From the animal studies, SGLT2 inhibitors could decrease oxidative stress in cardiomyocytes, reverse myocardial remodeling and reduce electronic alterations. These pleiotropic effects of